AIDS Vaccine Progress Published in Virology

A University of Kansas School of Medicine researcher’s success developing an AIDS vaccine was reported in the August issue of the peer-reviewed journal Virology. Opendra Narayan, DVM, PhD, and his collaborators have successfully prevented AIDS in animal trials using a DNA vaccine.

Narayan, chairman of the department of microbiology, molecular genetics and immunology at the KU School of Medicine and Marion Merrell Dow Foundation Distinguished Professor, has spent years conducting research on the vaccine. He says this evidence that the vaccine is working represents a big step toward clinical trials.

“It is proof that a vaccine can protect animals and the hope is that by extension the vaccine will protect humans,” Narayan said.
ImmunoGenetix Therapeutics, Inc. is the exclusive worldwide licensee of the vaccine.

“These findings from Dr. Narayan's team are very exciting for the company and give us confidence to take the steps toward an Investigational New Drug status and human trials,” said Jim Laufenberg, President and CEO of ImmunoGenetix. Narayan has been a consultant with the Lenexa-based biotechnology company since its founding in 2001. He says that the path to get the vaccine on the market is not a fast one.

“To move from an animal vaccine to humans requires a lot of changes. It is a very expensive and slow process. Once we complete justification with the FDA, then we’ll head to clinical trials,” Narayan says.

Narayan uses the simian/human immunodeficiency virus (SHIV), which closely resembles HIV infections in humans, to conduct animal trials. The vaccine takes the blueprint of the virus and deletes the genes that allow it to replicate. Because it is prevented from replicating, the virus can’t multiply and cause AIDS once it is in the body.

The DNA vaccine is different from vaccines that use a live virus to develop immunity. Because it uses DNA and not a live virus, there would be no risk for infection. DNA vaccines are also easier to produce and store.

Narayan says the next step in his research is investigating the strength of the immunity created by the vaccine. He says the immunity is there to protect the virus from replicating and causing AIDS, not to protect from infection. Narayan will study whether the animals will have the virus for life but never develop AIDS, or if the immunity is strong enough to completely shed the virus from the body.

While this vaccine is based on the strain of HIV found in the United States, Narayan is also working on vaccines for the strains found in other parts of the world. He is already developing one for the strain found in Africa and Asia, but it hasn’t gone on to animal trials yet.

According to UNAIDS, nearly 40 million people worldwide were living with HIV at the end of 2005, when an estimated 4 million people became newly infected with HIV and an estimated 3 million people lost their lives to AIDS.

The International Society for NeuroVirology awarded Dr. Narayan its 2006 Pioneer in NeuroVirology Award to recognize his accomplishments and contributions to the field during his nearly 40 years of experience. Dr. Narayan was recently named a charter member of the newly created COBRE/INBRE/RCMI review panel at the National Center for Research Resources, a division of the National Institutes of Health.

Source: University of Kansas School of Medicine

Related stories:

AIDS vaccine nears human testing
A University of Kansas Medical Center researcher hopes to get the funds needed for the next step in developing his AIDS vaccine -- testing on humans.
Scientists identify genetic link that may neutralize HIV
Scientists from the Gladstone Institute of Virology and Immunology (GIVI) and the National Institutes of Allergy and Infectious Diseases (NIAID) have identified a gene that may influence the production of antibodies that neutralize HIV. This new information will likely spur a new approach for making an HIV vaccine that elicits neutralizing antibodies. Neutralizing antibodies, once produced in the host, can attack and checkmate an infecting virus. The research was reported in the September 5 issue of Science.
Study shows no connection between measles, mumps, rubella (MMR) vaccine and autism
In a case-control study, the presence of measles virus RNA was no more likely in children with autism and GI disturbances than in children with only GI disturbances. Furthermore, GI symptom and autism onset were unrelated to MMR vaccine timing.
Study: No link between measles vaccine and autism
(AP) -- New research further debunks any link between measles vaccine and autism, work that comes as the nation is experiencing a surge in measles cases fueled by children left unvaccinated.
Scientists uncover Ebola cell-invasion strategy
University of Texas Medical Branch at Galveston researchers have discovered a key biochemical link in the process by which the Ebola Zaire virus infects cells — a critical step to finding a way to treat the deadly disease produced by the virus.
Scientists examine bird flu infections to monitor for 'pandemic' mutations
Scientists funded by the Wellcome Trust are to examine what is preventing the H5N1 avian influenza virus from causing a human pandemic and what mutations are required to realise its deadly potential. The research could hold the key to early identification of a potential influenza pandemic, and to developing drugs and a vaccine.
Flu shot does not reduce risk of death
The widely-held perception that the influenza vaccination reduces overall mortality risk in the elderly does not withstand careful scrutiny, according to researchers in Alberta. The vaccine does confer protection against specific strains of influenza, but its overall benefit appears to have been exaggerated by a number of observational studies that found a very large reduction in all-cause mortality among elderly patients who had been vaccinated.
Cervical cancer prevention should focus on vaccinating adolescent girls
The cost-effectiveness of vaccination in the United States against human papillomavirus (HPV), a sexually-transmitted virus that causes cervical cancer, will be optimized by achieving universal vaccine coverage in young adolescent girls, by targeting initial "catch-up" efforts to vaccinate women younger than 21 years of age, and by revising current screening policies, according to an analysis by Harvard School of Public Health (HSPH) researchers in the August 21, 2008 issue of The New England Journal of Medicine.

News discussion:

Medicine & Health news